search
Back to results

Epileptiform Activity During REM Sleep in Alzheimer's Disease (EREMAD)

Primary Purpose

Alzheimer Disease, Early Onset

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Overnight polysomnography
blood sample
high-resolution MRI scan
neuropsychological evaluation
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Alzheimer Disease, Early Onset focused on measuring Alzheimer's disease, Rapid eye movement (REM) sleep, Memory consolidation, Epilepsy, MRI

Eligibility Criteria

50 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

For all participants:

  • age from 50 to 90 years old
  • affiliated to the French health care system

For AD patients:

  • meeting International Working Group (IWG)-2 criteria for diagnosis
  • Mini-Mental State Examination (MMSE) ≥18 (Greco version)

For healthy volunteers:

  • MMSE>25
  • Dubois 5 words test ≥ 9

Exclusion Criteria:

For all participants:

  • Pregnancy
  • people not able to give consent
  • contraindication for MRI (metallic body parts, claustrophobia),
  • aphasia, apraxia or agnosia
  • neurological (other than AD) or any other serious disease (cancer, addiction, systemic disease)
  • non treated sleep apnea
  • major depression or anxiety for more than 3 months (Beck>10) or psychiatric disease
  • documented epilepsy
  • use of neuroleptics (more than one dose per day)
  • use of antiepileptics
  • use of benzodiazepines at a dose superior or equal to two intakes per day
  • use of antidepressants
  • restless leg syndrome treated by dopaminergic agonists.

For AD patients:

  • other causes of dementia
  • non-degenerative neurological lesions
  • white matter hypersignals
  • acute cognitive deficits

Sites / Locations

  • Toulouse University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Alzheimer's Disease patients group

Healthy control group

Arm Description

This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease

This group contains the 31 (anticipated) age and sex -matched healthy controls

Outcomes

Primary Outcome Measures

Epileptiform activity during REM sleep
the proportion of participants from each group exhibiting a significant epileptiform activity (seizures and/or interictal spikes) during REM sleep. . Epileptiform activity will be defined as either at least one spike, or at least 4 paroxysmal activities.

Secondary Outcome Measures

Number of epileptiform activity according to sleep-wake cycle
Number of epileptiform activity according to sleep-wake cycle in each group
Frequency of epileptiform activity according to sleep-wake cycle
Frequency of epileptiform activity according to sleep-wake cycle in each group
lateralization of epileptiform activity according to sleep-wake cycle
lateralization of epileptiform activity according to sleep-wake cycle in each group
localization of epileptiform activity according to sleep-wake cycle
localization of epileptiform activity according to sleep-wake cycle in each group
Comparison of sleep characterization between the two groups: total sleep time
total sleep time in hours and minutes
Comparison of sleep characterization between the two groups: number of sleep cycles
number of sleep cycles
Comparison of sleep characterization between the two groups: time spent awake during the night
time spent awake during the night
Comparison of sleep characterization between the two groups: index of micro-awakenings
index of micro-awakenings
Comparison of sleep characterization between the two groups: distribution of different sleep stages in time
distribution of different sleep stages in time
Comparison of sleep characterization between the two groups: distribution of different sleep stages in percentage
distribution of different sleep stages in percentage
Comparison of sleep characterization between the two groups: index of periodic movements
the index of periodic movements
Comparison of sleep characterization between the two groups: index of hypopnea
index of hypopnea (central and obstructive components)
Comparison of memory scores at the overnight retention test between the two groups
The memory scores are combined to compute a total score
symptoms of an underlying epileptic syndrome
The score on the questionnaire aiming at discovering potential symptoms of an underlying epileptic syndrome
sleep spindles in different sleep stages
The number and the density of sleep spindles in different sleep stages
results of the cognitive reserve inventory (CRIq)
Correlation between the frequency of epileptiform activity, the score on the epilepsy questionnaire and the index of micro-awakenings in the different sleep stages and: the results of the cognitive reserve inventory (CRIq)
speed of cognitive decline.
Correlation between the frequency of epileptiform activity, the score on the epilepsy questionnaire and the index of micro-awakenings in the different sleep stages and: the speed of cognitive decline.
density of sleep spindles in the different sleep stages
Correlation between the frequency of epileptiform activity, the score on the epilepsy questionnaire and the index of micro-awakenings in the different sleep stages and: the density of sleep spindles in the different sleep stages

Full Information

First Posted
March 29, 2019
Last Updated
July 20, 2021
Sponsor
University Hospital, Toulouse
Collaborators
Centre de Recherches sur la Cognition Animale (CRCA - UMR5169 CNRS/UPS), Centre de Recherche Cerveau & Cognition (CerCo - UMR5549 CNRS/UPS), Toulouse NeuroImaging Center (ToNIC - UMR 1214 Inserm/UPS), Fondation Plan Alzheimer, IHNPS/FHU HoPeS
search

1. Study Identification

Unique Protocol Identification Number
NCT03923569
Brief Title
Epileptiform Activity During REM Sleep in Alzheimer's Disease
Acronym
EREMAD
Official Title
Epileptiform Activity During REM Sleep in Alzheimer's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 29, 2019 (Actual)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
Collaborators
Centre de Recherches sur la Cognition Animale (CRCA - UMR5169 CNRS/UPS), Centre de Recherche Cerveau & Cognition (CerCo - UMR5549 CNRS/UPS), Toulouse NeuroImaging Center (ToNIC - UMR 1214 Inserm/UPS), Fondation Plan Alzheimer, IHNPS/FHU HoPeS

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Recent clinical data showed that patients with Alzheimer Disease (AD) might present epilepsy at early stages of the disease (Cretin et al., 2016, Vossel et al., 2016). In mice models of Alzheimer disease, preclinical researchers observed an increase of epileptic events during Rapid Eye Movement (REM) sleep, which is very unusual. This study aims at testing if patients with AD present an exacerbation of epileptic events during REM sleep, which could constitute an early biomarker of the disease. Investigators will evaluate the incidence of epilepsy during each sleep stage in 40 patients with early or moderate forms of AD and in 40 healthy subjects. Investigators will also look for a link between epilepsy during sleep in AD participants and memory performances, brain damage (by using MRI scans) and in the case of patients, the phenotype of the Apolipoprotein E(ApoE) gene.
Detailed Description
Preclinical researchers discovered that the Tg2576 mouse model of Alzheimer Disease (AD) presents epileptiform activity specifically during sleep, with a prominent increase during REM-sleep. This phenotype is specific to AD mice since REM-sleep usually prevents seizures and epileptiform activity in animal models of epilepsy. Preclinical research also evidenced that this epileptic phenotype occurs at very early age in Tg2576 mice, far before the onset of cognitive impairments. Thus, it was hypothesized that patients with AD might present subclinical epileptiform events during sleep with a potential worsening during REM-sleep. If so, it could be used as a specific and early biomarker of AD. Since sleep is involved in memory consolidation processes, preclinical researchers also hypothesized that epileptiform events during sleep might participate to cognitive dysfunction in AD patients. In order to test this hypothesis, a monocentric clinical study with a protocol consisting of three visits was designed aiming at evaluating seizures and subclinical epileptiform activity - and their consequences on memory - during sleep in 31 patients at early to moderate stages of AD and 31 matched healthy participants. During the first visit, a blood sample is collected of each patient for genetic testing of the ApoE gene before they undergo a high-resolution MRI scan. During the second visit (in the 60 days following the first one) participants first undergo a neuropsychological evaluation including visual, verbal and episodic memory tests before an overnight polysomnography. Following the overnight polysomnography, all subjects (patients and healthy participants) will be tested for the memories acquired the day before in order to evaluate sleep related memory consolidation. During the last visit, participants will fill out questionnaires aiming at evaluating pre-diagnostic lifestyle and they (and one family member if possible) will be interviewed about the presence of symptoms that might indicate an underlying epileptic syndrome for the participant. Healthy subjects will undergo the same procedures except for the blood test from which they will be exempted. This should allow to evidence sleep related epileptic events, to precise their incidence in AD patients as well as in healthy participants, and to correlate these events to anomalies in brain structure and functional resting state connectivity (MRI) and/or sleep disturbances and/or cognitive decline.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease, Early Onset
Keywords
Alzheimer's disease, Rapid eye movement (REM) sleep, Memory consolidation, Epilepsy, MRI

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
2 compared groups (Alzheimer's Disease patients vs controls)
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
62 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Alzheimer's Disease patients group
Arm Type
Other
Arm Description
This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease
Arm Title
Healthy control group
Arm Type
Other
Arm Description
This group contains the 31 (anticipated) age and sex -matched healthy controls
Intervention Type
Diagnostic Test
Intervention Name(s)
Overnight polysomnography
Intervention Description
Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
Intervention Type
Diagnostic Test
Intervention Name(s)
blood sample
Intervention Description
blood sample for genetic testing of the Apolipoprotein E
Intervention Type
Diagnostic Test
Intervention Name(s)
high-resolution MRI scan
Intervention Description
Evaluation of anomalies in brain structure and functional resting state connectivity
Intervention Type
Behavioral
Intervention Name(s)
neuropsychological evaluation
Intervention Description
neuropsychological evaluation including episodic memory tests before an overnight polysomnography
Primary Outcome Measure Information:
Title
Epileptiform activity during REM sleep
Description
the proportion of participants from each group exhibiting a significant epileptiform activity (seizures and/or interictal spikes) during REM sleep. . Epileptiform activity will be defined as either at least one spike, or at least 4 paroxysmal activities.
Time Frame
Day 2
Secondary Outcome Measure Information:
Title
Number of epileptiform activity according to sleep-wake cycle
Description
Number of epileptiform activity according to sleep-wake cycle in each group
Time Frame
Day 2
Title
Frequency of epileptiform activity according to sleep-wake cycle
Description
Frequency of epileptiform activity according to sleep-wake cycle in each group
Time Frame
Day 2
Title
lateralization of epileptiform activity according to sleep-wake cycle
Description
lateralization of epileptiform activity according to sleep-wake cycle in each group
Time Frame
Day 2
Title
localization of epileptiform activity according to sleep-wake cycle
Description
localization of epileptiform activity according to sleep-wake cycle in each group
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: total sleep time
Description
total sleep time in hours and minutes
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: number of sleep cycles
Description
number of sleep cycles
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: time spent awake during the night
Description
time spent awake during the night
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: index of micro-awakenings
Description
index of micro-awakenings
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: distribution of different sleep stages in time
Description
distribution of different sleep stages in time
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: distribution of different sleep stages in percentage
Description
distribution of different sleep stages in percentage
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: index of periodic movements
Description
the index of periodic movements
Time Frame
Day 2
Title
Comparison of sleep characterization between the two groups: index of hypopnea
Description
index of hypopnea (central and obstructive components)
Time Frame
Day 2
Title
Comparison of memory scores at the overnight retention test between the two groups
Description
The memory scores are combined to compute a total score
Time Frame
Day 2
Title
symptoms of an underlying epileptic syndrome
Description
The score on the questionnaire aiming at discovering potential symptoms of an underlying epileptic syndrome
Time Frame
Month 5
Title
sleep spindles in different sleep stages
Description
The number and the density of sleep spindles in different sleep stages
Time Frame
day 2
Title
results of the cognitive reserve inventory (CRIq)
Description
Correlation between the frequency of epileptiform activity, the score on the epilepsy questionnaire and the index of micro-awakenings in the different sleep stages and: the results of the cognitive reserve inventory (CRIq)
Time Frame
month 5
Title
speed of cognitive decline.
Description
Correlation between the frequency of epileptiform activity, the score on the epilepsy questionnaire and the index of micro-awakenings in the different sleep stages and: the speed of cognitive decline.
Time Frame
month 5
Title
density of sleep spindles in the different sleep stages
Description
Correlation between the frequency of epileptiform activity, the score on the epilepsy questionnaire and the index of micro-awakenings in the different sleep stages and: the density of sleep spindles in the different sleep stages
Time Frame
month 5

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: For all participants: age from 50 to 90 years old affiliated to the French health care system For AD patients: meeting International Working Group (IWG)-2 criteria for diagnosis Mini-Mental State Examination (MMSE) ≥18 (Greco version) For healthy volunteers: MMSE>25 Dubois 5 words test ≥ 9 Exclusion Criteria: For all participants: Pregnancy people not able to give consent contraindication for MRI (metallic body parts, claustrophobia), aphasia, apraxia or agnosia neurological (other than AD) or any other serious disease (cancer, addiction, systemic disease) non treated sleep apnea major depression or anxiety for more than 3 months (Beck>10) or psychiatric disease documented epilepsy use of neuroleptics (more than one dose per day) use of antiepileptics use of benzodiazepines at a dose superior or equal to two intakes per day use of antidepressants restless leg syndrome treated by dopaminergic agonists. For AD patients: other causes of dementia non-degenerative neurological lesions white matter hypersignals acute cognitive deficits
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luc Valton, MD
Phone
05-61-77-94-88
Ext
33
Email
valton.l@chu-toulouse.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Lionel Dahan, PHD
Phone
06.43.18.23.16
Ext
33
Email
lionel.dahan@univ-tlse3.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lionel Dahan, PHD
Organizational Affiliation
Centre de Recherches sur la Cognition Animale (CRCA), UMR CNRS 5169
Official's Role
Study Director
Facility Information:
Facility Name
Toulouse University Hospital
City
Toulouse
State/Province
Occitanie
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brigitte POUZET
Phone
33 5 61 77 91 25
Email
brigitte.pouzet@inserm.fr
First Name & Middle Initial & Last Name & Degree
Jérémie PARIENTE, MD, PHD
First Name & Middle Initial & Last Name & Degree
Claire THALAMAS, MD
First Name & Middle Initial & Last Name & Degree
Fabienne CALVAS, MD
First Name & Middle Initial & Last Name & Degree
Rachel DEBS, MD
First Name & Middle Initial & Last Name & Degree
Marie DENUELLE, MD
First Name & Middle Initial & Last Name & Degree
Monique GALITZKY, MD
First Name & Middle Initial & Last Name & Degree
Luc VALTON, MD
First Name & Middle Initial & Last Name & Degree
Florence RULQUIN, MD
First Name & Middle Initial & Last Name & Degree
Helène CATALA, MD

12. IPD Sharing Statement

Learn more about this trial

Epileptiform Activity During REM Sleep in Alzheimer's Disease

We'll reach out to this number within 24 hrs